CYFIP-MV-9R
The cell line is not validated yet.
RCPCMi012-A
General
Cell Line |
|
hPSCreg name | RCPCMi012-A |
Cite as: | RCPCMi012-A |
Alternative name(s) |
CYFIP-MV-9R
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 20th April 2025 |
User feedback | |
Provider |
|
Generator | Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency (RCPCM) |
Owner | Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency (RCPCM) |
Derivation country | Russia |
External Databases |
|
BioSamples | SAMEA117685500 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | neonate |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Sanger sequencing of a gene region
|
External Databases (Donor) |
|
BioSamples | SAMEA117654133 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Alternatives to consent are available? | No |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
* Does consent expressly prevent the derivation of pluripotent stem cells? | No |
* Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Does consent expressly permit storage of genetic information? | Yes |
Does consent prevent dissemination of genetic information? | No |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency of Russian Ministry of Health |
Approval number | no. 1 |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
Age of donor (at collection) | neonate |
Collected in | 2022 |
Passage number reprogrammed | 3 |
Reprogramming method |
|
Vector type | None |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
mRNA
|
mRNA | |
Other |
|
Selection criteria for clones | morphology and stable karyotype |
Derived under xeno-free conditions |
Yes |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzymatically
TrypLE
|
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|||||
SALL-4 |
Yes |
|
||||
NANOG |
Yes |
|||||
SOX2 |
Yes |
|||||
SSEA-4 |
Yes |
|||||
TRA 1-81 |
Yes |
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Sanger sequencing of a gene region
found missense mutation p.Arg87Cys in the CYFIP2 gene |
Login to share your feedback, experiences or results with the research community.